Background

Phase 1 wantlist hit, foundational drug-policy document. The 1991 Vincent memo is the operational framework for MLB drug discipline that preceded the post-2002 jointly-bargained Joint Drug Agreement. The critical structural feature is the MLB-player carve-out from unannounced testing (Section 2.A) — major leaguers could only be tested if they had previously admitted to or been detected using drugs, which created the gap that allowed substantially undetected drug use (including steroids) to proceed throughout the 1990s and early 2000s until the post-2002 JDA imposed random testing across all MLB players. Fay Vincent was Commissioner from September 1989 (after the Bart Giamatti era ended with Giamatti's death on Sept 1, 1989) until his September 1992 resignation following the owners' 18-9 no-confidence vote that ended his tenure during the labor crisis preceding the 1994-95 strike. Louis Melendez as Associate Counsel to the MLB Player Relations Committee was the operational steward of the program; Melendez was later Senior VP of International and Minor League Operations at MLB. CompuChem Laboratories at Research Triangle Park, NC was the NIDA-certified facility — that the program contracted with a federally-certified lab and used GC/MS confirmatory testing is a notable detail that distinguishes the formal-structure-but-limited-applicability of this program from the post-2002 JDA. The Bates-stamped 'MLB 000122–MLB 000128' numbering on the document indicates this was a copy from MLB document production, likely in connection with the Mitchell Report investigation (2006-2007) or related drug-policy litigation. Doctrinal significance: this memo is the operational baseline against which every subsequent MLB drug-policy revision must be measured. The 'no unannounced testing of MLB players' carve-out is the structural feature that defines why the steroid era happened on MLB's watch — the policy ostensibly prohibited PED use but the testing regime made enforcement at the MLB level essentially impossible. The transition from this memo to the post-2002 JDA framework is the labor-union victory of imposing actual testing protocols on all MLB players (jointly bargained, not unilaterally imposed by the commissioner) — a structural pattern that recurs throughout MLB labor-policy history.

Key provisions

• Issuance: Memorandum 1.20 from Francis T. Vincent, Jr., Commissioner of Major League Baseball, dated June 7, 1991, to all Major League Clubs (cc: League Presidents, Player Relations Committee, MLBPA).
• Substantive prohibition: 'The possession, sale or use of any illegal drug or controlled substance by Major League players and personnel is strictly prohibited.' Includes 'steroids or prescription drugs for which the individual in possession of the drug does not have a prescription.' Discipline up to permanent expulsion. Club fine for cover-up: $250,000 (highest under the Major League Agreement at that time).
• Section 1 — Employee Assistance Programs (EAPs): Each Club required to maintain an EAP for major and minor league players and personnel. Confidential independent counseling. EAP is the principal point of intervention.
• Section 2 — Testing: Drug testing as the deterrent and detection mechanism. Tested substances: cocaine, marijuana, amphetamines, opiates, and phencyclidine (PCP). Other drugs may be added with prior notice. No steroids listed for testing despite the prohibition.
• Section 2.A — Major League Players (critical limit): 'Major League players are not subject to unannounced testing for illegal drugs. However, Major League players who have admitted to illegal drug use, or who have been detected using illegal drugs, are subject to mandatory testing as a component of the player's aftercare program for the remainder of the player's career.' This is the structural gap that allowed steroid use to proceed substantially undetected at the MLB level until the post-2002 JDA.
• Section 2.B — Minor League Players: ALL minor league players subject to unannounced testing, conducted consistent with applicable state law.
• Section 2.C — Amateur Entry Level Players: All amateur entry-level players, whether selected in June draft or not, tested for illegal drug use.
• Section 2.D — Major and Minor League Non-Playing Personnel: ALL non-playing personnel subject to unannounced testing.
• Section 4 — Testing Times: Samples taken 'no more than four times per season' (March-October) for any individual; off-season testing 'if necessary.'
• Section 6 — Laboratories: CompuChem Laboratories of Research Triangle Park, North Carolina, NIDA-certified, conducting gas chromatography/mass spectrometry (GC/MS) confirmatory testing on screening positives.
• Section 7 — Discipline: First positive test → EAP without loss of pay. Refusal to enter or cooperate with EAP → discipline imposed. Second positive → immediate discipline. Sale/distribution → immediate discipline. Drug-related criminal conviction → immediate discipline regardless of EAP status.
• Section 9 — Confidentiality: 'Confidentiality of players' and other Baseball personnel's medical conditions and test results will be protected to the maximum extent possible.' Program directors and lab prohibited from public disclosure. Discipline for Clubs, players, or personnel who publicly disclose test results or breach confidentiality.
• Contact: Louis Melendez, Associate Counsel, MLB Player Relations Committee (the operational point of contact for the program).

Notable provisions

The basic drug policy for the game is simply stated: There is no place for illegal drug use in Baseball. The use of illegal drugs by players, umpires, owners, front office, League or Commissioner's office personnel, trainers or anyone else involved in the game cannot be condoned or tolerated.— Vincent Memo, Introduction (June 7, 1991)

This prohibition applies to all illegal drugs and controlled substances, including steroids or prescription drugs for which the individual in possession of the drug does not have a prescription.— Vincent Memo, Major League Baseball's Drug Policy

Major League players are not subject to unannounced testing for illegal drugs. However, Major League players who have admitted to illegal drug use, or who have been detected using illegal drugs, are subject to mandatory testing as a component of the player's aftercare program for the remainder of the player's career.— Vincent Memo, Section 2.A — Major League Players

Samples will be tested for the following controlled substances: cocaine, marijuana, amphetamines, opiates and phencyclidine (PCP). Other drugs may be added to this list if necessary and with prior notice.— Vincent Memo, Section 2 — Testing

Confidentiality of players' and other Baseball personnel's medical conditions and test results will be protected to the maximum extent possible, recognizing that individuals who violate Baseball's prohibition on illegal drug or controlled substance use will come to the attention of the public and the media, often in the case of players because of the roster moves necessitated by the loss of the player's services to the Club.— Vincent Memo, Section 9 — Confidentiality

Further context

1991 Vincent Drug Memo

The formal MLB drug policy document of the pre-JDA era, issued by Commissioner Fay Vincent on June 7, 1991. Phase 1 wantlist item, foundational document.

The critical structural feature

The Vincent memo prohibited drug use across all MLB players and personnel. But Section 2.A carved Major League players out from unannounced testing — they could only be tested if they had previously admitted to or been detected using drugs. Minor leaguers, amateurs, and non-playing personnel were all subject to unannounced random testing. MLB players were not.

This is the structural gap that allowed the steroid era to proceed substantially undetected at the MLB level for over a decade. The policy formally banned the substances; the testing regime made enforcement essentially impossible.

What was actually tested

Section 2 lists the specific tested substances: cocaine, marijuana, amphetamines, opiates, and phencyclidine (PCP). Steroids were prohibited but not listed for testing. The discrepancy is structural rather than technical — by 1991, GC/MS testing for anabolic steroids was technically feasible (the Olympics had been doing it), but MLB's policy didn't include them in the standard panel.

How it transitioned

The 1991 Vincent memo was effectively the operational baseline until the post-2002 JDA imposed jointly-bargained random testing across all MLB players. The 1997 Selig memo (separate document, still on the wantlist) was an intermediate update; the JDA framework starting with the 2002-2006 CBA was the structural transformation.

Why this matters

The structural critique: a "drug policy" that prohibited a substance without testing for it, and that exempted the relevant population from unannounced testing, is exactly the framework that produces the steroid era. The labor-union victory in the 2002 CBA was forcing real testing into the agreement — at the cost of the commissioner losing unilateral authority over drug discipline.

Related documents

• 1997_memo_selig-drug-policy-program.md (wantlist) — successor unilateral memo.
• 2022-01-01_policy_joint-drug-prevention-treatment-program.md — current jointly-bargained framework descended from the post-2002 JDA.

Verification status

needs_review. Single secondary source (BoB via Wayback). Bates-stamped document-production copy provides strong internal authentication. Second-source confirmation pending — Mitchell Report appendix or SABR copy would likely match.

Related documents

Superseded by

1997 Selig Drug Memo

Related documents

1997 Selig Drug Memo, Joint Drug Program (2022–2026)

Source provenance

• Primary source
• Wayback Machine archive